Search





Search





Markets
/
Stocks
/
nasdaq-rprx
/

Royalty Pharma PLC

RPRX

Add to Watchlist

50.790USD

+0.590+1.18%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

29.25BMarket Cap

26.44P/E TTM



Royalty Pharma PLC

50.790

+0.590+1.18%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Royalty Pharma PLC

Currency: USD Updated: 2026-05-08

Key Insights

Royalty Pharma PLC's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 7 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 52.99.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Royalty Pharma PLC's Score

Industry at a Glance

Industry Ranking

7 / 156

Overall Ranking

42 / 4494

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Royalty Pharma PLC Highlights

StrengthsRisks

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 17 development-stage product candidates.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 43.83%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 43.83%.

Overvalued

The company’s latest PE is 26.44, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 382.59M shares, increasing 0.40% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 3.34K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

57.111

Target Price

+13.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Royalty Pharma PLC is 8.61, ranking 38 out of 156 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 630.58M, representing a year-over-year increase of 10.97%, while its net profit experienced a year-over-year increase of 23.64%.

Score

Industry at a Glance

Previous score

8.61

Change



Financials

5.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Royalty Pharma PLC's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Royalty Pharma PLC is 7.60, ranking 57 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 26.44, which is 1423.79% below the recent high of 402.86 and 64.06% above the recent low of 9.50.

Score

Industry at a Glance

Previous score

7.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 7/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Royalty Pharma PLC is 8.40, ranking 39 out of 156 in the Pharmaceuticals industry. The average price target is 45.00, with a high of 56.00 and a low of 34.67.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

57.111

Target Price

+13.77%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Royalty Pharma PLC

RPRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Royalty Pharma PLC is 9.13, ranking 32 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 52.36 and the support level at 48.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.93

Change

0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.009

Neutral

RSI(14)

64.459

Neutral

STOCH(KDJ)(9,3,3)

60.772

Neutral

ATR(14)

1.010

High Vlolatility

CCI(14)

162.949

Buy

Williams %R

31.047

Buy

TRIX(12,20)

0.242

Sell

StochRSI(14)

65.349

Neutral

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

50.470

Buy

MA10

50.059

Buy

MA20

49.627

Buy

MA50

47.846

Buy

MA100

44.652

Buy

MA200

40.912

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Royalty Pharma PLC is 7.00, ranking 47 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 86.10%, representing a quarter-over-quarter increase of 4.21%. The largest institutional shareholder is Baillie Gifford, holding a total of 17.01M shares, representing 3.84% of shares outstanding, with 20.64% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Morgan Stanley Investment Management Inc. (US)

37.31M

+2.30%

Capital International Investors

31.10M

+14.30%

Nogra Group Sicaf SIF S.A.

24.22M

-19.06%

Fidelity Management & Research Company LLC

21.67M

-5.80%

BlackRock Institutional Trust Company, N.A.

17.79M

+3.11%

Baillie Gifford & Co.

Star Investors

17.01M

-2.09%

Morgan Stanley & Co. LLC

12.86M

+326.86%

Adage Capital Management, L.P.

11.74M

-1.88%

Swedbank Robur Fonder AB

11.94M

-2.12%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Royalty Pharma PLC is 9.15, ranking 16 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.39. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Royalty Pharma PLC’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.